216167-95-2

Basic information

• Product Name: ELSIBUCOL
• Synonyms: ELSIBUCOL;Butanoic acid,4-[4-[[1-[[3,5-bis(1,1-diMethylethyl)-4-hydroxyphenyl]thio]-1-Methylethyl]thio]-2,6-bis(1,1-diMethylethyl)phenoxy]-;AGI 1096;4-(2,6-di-tert-butyl-4-(2-(3,5-di-tert-butyl-4-hydroxyphenylthio)propan-2-ylthio)phenoxy)butanoic acid;YHFUPQNXMNMQAK-UHFFFAOYSA-N
• CAS NO: 216167-95-2
• Molecular Formula: C₃₅H₅₄O₄S₂
• Molecular Weight: 602.94
• Mol File: 216167-95-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ELSIBUCOL(CAS DataBase Reference)
• NIST Chemistry Reference: ELSIBUCOL(216167-95-2)
• EPA Substance Registry System: ELSIBUCOL(216167-95-2)

Safety Data

• Hazardous Substances Data: 216167-95-2(Hazardous Substances Data)

Usage

Uses

Prevention of solid organ transplant rejection.

Upstream product

• 3153-37-5 methyl 4-chlorobutyrate 
• 23288-49-5 (4,4'-isopropylidenedithio)bis[2,6-di-tert-butylphenol] 
• 216168-59-1 methyl 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]butyrate 

Relevant articles and documents

Process for preparation of probucol derivatives and polymorphic forms thereof

A process is described for the preparation of polymorphic forms of water-soluble derivatives of probucol compounds. The process generally includes reacting a probucol compound with a solution of alkali metal oxide, reacting the salt mixture with a solutio

Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases

Vascular cell adhesion molecule-1 (VCAM-1) mediates recruitment of leukocytes to endothelial cells and is implicated in many inflammatory conditions. Since part of the signal transduction pathway that regulates the activation of VCAM-1 expression is redox

Compounds and methods for treating transplant rejection

The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.

Compounds and methods of treating transplant rejection

The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are defined in the application.

Compounds and methods for treating transplant rejection

The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.